CFHR3 LYTAC (Novartis)

N/A

Report date: 2026/04/27 20:02:09

Base Information

Drug NameCFHR3 LYTAC (Novartis)
Drug Alias NameN/A
ClassificationBiologics > Lysosome-Targeting Chimaeras (LYTAC)
Mechanisms of ActionComplement factor H-related protein 3 degraders
TargetsComplement factor H-related protein 3
Therapy Area/IndicationsAtypical Hemolytic Uremic SyndromeNephrosisMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Ag
Inactive CompaniesN/A
Active IndicationsAtypical Hemolytic Uremic SyndromeNephrosisMacular Degeneration +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A